FORM 4

## **UNITED STATES SECURITIES AND EXCHANGE COMMISSION**

Washington, [	D.C. 20549
---------------	------------

Check this box if no longer subject
to Section 16. Form 4 or Form 5
obligations may continue. See
Instruction 1(b).

## STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

OMB APPROVAL 3235-0287 Estimated average burden hours per response: 0.5

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940

1. Name and Address of Reporting Person*  Takimoto Chris H					2. Issuer Name <b>and</b> Ticker or Trading Symbol IGM Biosciences, Inc. [ IGMS ]									(Ch	neck all app Direct Office	ionship of Reporti all applicable) Director Officer (give title		son(s) to Is: 10% Ow Other (s	wner
(Last) (First) (Middle) C/O IGM BIOSCIENCES, INC. 325 E. MIDDLEFIELD ROAD				3. Date of Earliest Transaction (Month/Day/Year) 11/15/2021										pelov	v) Chief Med	lical O	below) Officer		
(Street) MOUNT VIEW	C.F		4043		4. If A	Amend	ment,	Date o	f Origina	al File	d (Month/Da	ay/Yea	ar)	Lin	e) <mark>X</mark> Form	r Joint/Grou filed by One filed by Mo on	e Repo	rting Perso	on
(City)	(51		Zip) I - <b>No</b> i	n-Deriva	tive S	Secu	rities	Acq	uired,	, Dis	posed of	f, or	Bene	eficia	ılly Own	ed			
1. Title of Security (Instr. 3)  2. Transac Date (Month/Date)					Exec if an	Deemed Lution Date, / hth/Day/Year)		3. Transaction Code (Instr. 8)  4. Securitie Disposed C 5)						d Securi Benefi Owned	cially I Following	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)		7. Nature of Indirect Beneficial Ownership (Instr. 4)	
										v	Amount	mount (A) or (D)		Price	Transa	Reported Transaction(s) (Instr. 3 and 4)			(IIIsti. 4)
Common Stock 11/15/2				2021				A		10,000(1)		A	\$0.0	0 1	0,000		D		
	Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)																		
1. Title of Derivative Security (Instr. 3)	ive Conversion Date Execution Date, y or Exercise (Month/Day/Year) if any		ion Date,	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)			7. Title and Amount of Securities Underlying Derivative Security (Inst 3 and 4)		,	8. Price of Derivative Security (Instr. 5)	9. Number derivative Securities Beneficially Owned Following Reported Transaction (Instr. 4)	Owner Form: Direct or Indi (I) (Inst	Ownership	11. Nature of Indirect Beneficial Ownership (Instr. 4)	
					Code	v	(A)	(D)	Date Exercis	sable	Expiration Date	Title	or Nun of	ount nber ires					

## **Explanation of Responses:**

1. These securities are restricted stock units (RSUs). Each RSU represents a contingent right to receive one share of the Issuer's Common Stock. One-fourth of the RSUs will vest on each of May 23, 2022, November 22, 2022, May 22, 2023, and November 22, 2023, provided that the Reporting Person remains a service provider through each vesting date.

## Remarks:

/s/ Misbah Tahir, by power of <u>attorney</u>

11/19/2021

\*\* Signature of Reporting Person Date

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

- \* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
- \*\* Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.